Menu Back toS28-Global-Oncology-Development-Be-a-Game-Changer-in-Oncology-Development

16th DIA Japan Annual Meeting 2019

Delivering Rational Medicine for All People in the Globe

[S28] Global Oncology Development - Be a Game Changer in Oncology Development -

Session Chair(s)

Hironobu  Saito, PhD

Hironobu Saito, PhD

  • Corporate Officer /Head of Medical Affairs Div.
  • Daiichi Sankyo Co., Ltd., Japan
The world surrounding cancer treatment continues to evolve rapidly. New, emerging products include not only immuno-oncology drugs, but also regenerative medicine and medical devices, that expand the therapeutic choice in the field of cancer treatment. Thanks to the rapidly evlolving digital applications, artificial intelligence (AI), and the Internet of Things (IoT) that affect clinical trial operations, clinical development faces both challenge and opportunity to keep the evaluation of novel therapeutic products simple and reliable. This session provides a great opportunity to discuss how we can move towards ideal future direction of global clinical trial in oncology. This is a pre-session for DIA Global Oncology Development 2020 held on Jan 31, 2020.


Eri  Sekine

Opportunities for More Contribution to Clinical Trials

Eri Sekine

  • Department Head, Trial Monitoring, Japan Development, Global Development Ops.
  • Novartis Pharma K.K., Japan
Toshiko  Ishibashi, PhD, RN

Site Capability for Global Study - from Both “ Sites and Sponsors” Perspectives

Toshiko Ishibashi, PhD, RN

  • Clinical Operation I, Clinical Operation Management
  • Ono Pharmaceutical Co., Ltd., Japan